Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx Countermeasures: HHS Launching "Pivotal Studies" To Engage Industry

Executive Summary

HHS is hoping to redefine its relationship with biotech and pharmaceutical firms that are developing Rx countermeasures though a series of "pivotal studies" under which government works more closely with industry at the beginning stages of development

You may also be interested in...

FDA Regulatory Science Gets The Flu (Funding) In HHS Overhaul Of Bioterror Product Development

Agency to receive $170 million for regulatory sciences initiative in recognition of the need for smother development pathway for medical countermeasures.

VentureHHS: Government Fund Would Invest In Firms Developing Medical Countermeasures

While BARDA focuses on products, the new fund would support the viability of developers, NIAID Director Fauci says

Financial Incentives Seen As A Path To Resurgence Of Antibiotics

As calls to develop novel antibiotics to treat drug-resistant bacteria grow louder, financial incentives remain a focus in the search for options to stimulate drug discovery

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts